The advanced research of immunotherapy in Epidermal growth factor receptor mutation-positive non-small cell lung cancer
{{output}}
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become the standard first-line treatment for advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. As resistance to EGFR-TKIs is associated with significantly worse prognos... ...
